On 2 September 2026 the FDA approved a supplemental application to NDA 213312 — Fyarro, sirolimus protein-bound particles for injectable suspension, held by Aadi Bioscience.
The approvals record gives the application, the sponsor and the active moiety, and nothing more. Supplemental approvals cover a wide range: a new indication, a labelling or safety change, a manufacturing or packaging change. Which of those this is cannot be read from the entry, so the only accurate statement is that the application was amended and approved on that date, and that what changed has to be taken from the Drugs@FDA record itself.
What is unchanged is the drug's place in practice. Nab-sirolimus is licensed in the United States for advanced malignant perivascular epithelioid cell tumour, a rare sarcoma, and this posting is not a new approval or a new indication. For Indian practice the constraint is availability rather than regulatory status: the agent is not routinely accessible here, and a US supplemental approval says nothing about the CDSCO position.
- Check the Drugs@FDA entry before treating a supplemental approval as clinically meaningful.
- This is not a new approval; nab-sirolimus remains licensed for advanced malignant PEComa in the US.
- Do not relay a supplemental approval to a patient as a change in their treatment.
- US supplemental approvals carry no implication for CDSCO status or Indian availability.
- Where a label does change, dosing, monitoring and interactions are the parts that reach the clinic.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free